S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and McCarthy reach a final deal to avoid US default and now must sell it to Congress
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and McCarthy reach a final deal to avoid US default and now must sell it to Congress
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and McCarthy reach a final deal to avoid US default and now must sell it to Congress
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and McCarthy reach a final deal to avoid US default and now must sell it to Congress
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
NASDAQ:RANI

Rani Therapeutics (RANI) Stock Forecast, Price & News

$4.19
+0.08 (+1.95%)
(As of 05/26/2023 ET)
Compare
Today's Range
$4.10
$4.35
50-Day Range
$3.92
$6.33
52-Week Range
$3.65
$13.44
Volume
90,086 shs
Average Volume
82,710 shs
Market Capitalization
$207.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.00

Rani Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
448.9% Upside
$23.00 Price Target
Short Interest
Bearish
4.28% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.63mentions of Rani Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$334,923 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.44) to ($1.71) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.93 out of 5 stars

Medical Sector

700th out of 1,012 stocks

Pharmaceutical Preparations Industry

352nd out of 495 stocks


RANI stock logo

About Rani Therapeutics (NASDAQ:RANI) Stock

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.

Receive RANI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rani Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RANI Stock News Headlines

"Unknown laser company making HUGE profit from Russia-Ukraine War"
On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>
3 Free Stock Picks per Day
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
8-K: Rani Therapeutics Holdings, Inc.
See More Headlines
Receive RANI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rani Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RANI Company Calendar

Last Earnings
3/22/2023
Today
5/28/2023
Next Earnings (Estimated)
8/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RANI
Fax
N/A
Employees
114
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$23.00
High Stock Price Forecast
$24.00
Low Stock Price Forecast
$22.00
Forecasted Upside/Downside
+448.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-30,590,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$2.72 million
Book Value
$1.24 per share

Miscellaneous

Free Float
24,737,000
Market Cap
$207.36 million
Optionable
Not Optionable
Beta
0.33

Key Executives

  • Mr. Mir A. Imran (Age 66)
    Exec. Chairman
    Comp: $33.33k
  • Mr. Talat Imran (Age 41)
    CEO & Director
    Comp: $1.07M
  • Mr. Svai S. Sanford (Age 52)
    Chief Financial Officer
    Comp: $675.74k
  • Dr. Mir Hashim (Age 62)
    Chief Scientific Officer
    Comp: $696.92k
  • Mr. Eric Groen
    Gen. Counsel
  • Ms. Bella Vazquez
    VP of HR













RANI Stock - Frequently Asked Questions

Should I buy or sell Rani Therapeutics stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rani Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RANI shares.
View RANI analyst ratings
or view top-rated stocks.

What is Rani Therapeutics' stock price forecast for 2023?

4 brokers have issued 1-year price objectives for Rani Therapeutics' shares. Their RANI share price forecasts range from $22.00 to $24.00. On average, they predict the company's share price to reach $23.00 in the next twelve months. This suggests a possible upside of 448.9% from the stock's current price.
View analysts price targets for RANI
or view top-rated stocks among Wall Street analysts.

How have RANI shares performed in 2023?

Rani Therapeutics' stock was trading at $5.90 at the beginning of the year. Since then, RANI stock has decreased by 29.0% and is now trading at $4.19.
View the best growth stocks for 2023 here
.

Are investors shorting Rani Therapeutics?

Rani Therapeutics saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 724,900 shares, an increase of 18.3% from the April 30th total of 612,700 shares. Based on an average daily volume of 53,200 shares, the short-interest ratio is presently 13.6 days. Currently, 4.3% of the company's stock are short sold.
View Rani Therapeutics' Short Interest
.

When is Rani Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023.
View our RANI earnings forecast
.

How were Rani Therapeutics' earnings last quarter?

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) issued its quarterly earnings data on Wednesday, March, 22nd. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.34) by $0.01. During the same period in the previous year, the business posted ($0.27) earnings per share.

When did Rani Therapeutics IPO?

(RANI) raised $100 million in an IPO on Friday, July 30th 2021. The company issued 6,666,667 shares at $14.00-$16.00 per share.

What is Rani Therapeutics' stock symbol?

Rani Therapeutics trades on the NASDAQ under the ticker symbol "RANI."

Who are Rani Therapeutics' major shareholders?

Rani Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Alphabet Inc. (0.91%), Susquehanna International Group LLP (0.14%), Renaissance Technologies LLC (0.08%), HRT Financial LP (0.04%), Bank of America Corp DE (0.03%) and Icon Wealth Partners LLC (0.03%). Insiders that own company stock include Cortes Isidoro Alfonso Quiroga, Mir A Imran and South Cone Investments Limited.
View institutional ownership trends
.

How do I buy shares of Rani Therapeutics?

Shares of RANI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Rani Therapeutics' stock price today?

One share of RANI stock can currently be purchased for approximately $4.19.

How much money does Rani Therapeutics make?

Rani Therapeutics (NASDAQ:RANI) has a market capitalization of $207.36 million and generates $2.72 million in revenue each year. The company earns $-30,590,000.00 in net income (profit) each year or ($1.32) on an earnings per share basis.

How many employees does Rani Therapeutics have?

The company employs 114 workers across the globe.

How can I contact Rani Therapeutics?

The official website for the company is www.ranitherapeutics.com. The company can be reached via phone at 408-457-3700 or via email at ir@ranitherapeutics.com.

This page (NASDAQ:RANI) was last updated on 5/28/2023 by MarketBeat.com Staff

My Account -